docetaxel + capecitabine + epirubicin + cyclophosphamide

This is a multi-agent chemotherapy regimen combining four drugs—docetaxel, capecitabine, epirubicin, and cyclophosphamide—used primarily in the treatment of breast cancer. - **Docetaxel** is a taxane that inhibits microtubule depolymerization, disrupting mitosis and leading to cell death. - **Capecitabine** is an oral prodrug converted to 5-fluorouracil (5-FU) in tumor tissue; it inhibits thymidylate synthase, interfering with DNA synthesis. - **Epirubicin** is an anthracycline that intercalates into DNA and inhibits topoisomerase II, causing DNA breaks and apoptosis. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA strands, preventing cell replication. This combination has been studied as adjuvant therapy for early-stage or high-risk breast cancer—including triple-negative subtypes—and in advanced/metastatic settings[1][2][4]. The regimen leverages different mechanisms of action for synergistic antitumor effects.